anti-Human Papilloma Virus Type 18 (HPV) E6 antibody product blog
Tags: Antibody; Monoclonal Antibody; Human Papilloma Virus Type 18 (HPV) E6; anti-Human Papilloma Virus Type 18 (HPV) E6 antibody;
The Human Papilloma Virus Type 18 (HPV) E6 n/a (Catalog #MBS311728) is an Antibody produced from Host: MouseSource: Ascites and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Human Papilloma Virus Type 18 (HPV) E6 can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry - Paraffin, Immunoprecipitation, Western Blot. Researchers should empirically determine the suitability of the Human Papilloma Virus Type 18 (HPV) E6 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Immunogen: Gel-purified HPV 18 E6-beta galactosidase fusion protein
Affinity Constant: Not determined. Buffer: 10mM Sodium phosphate, pH 7.4 containing 150mM Sodium chloride
Preservative: 0.1% Sodium azide
Important Note: Centrifuge before opening to ensure complete recovery of vial contents.
Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1-1.0%. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Human Papilloma Virus Type 18 (HPV) E6 are readily searchable from our website. Different antibodies against the same target such as Human Papilloma Virus Type 18 (HPV) E6 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.